Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Arsenic Trioxide in MDS
NCT03377725Phase 3Withdrawn
- Start
- Mar 2018
- Primary completion
- Mar 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of arsenic trioxide in myelodysplastic syndrome (MDS) (2 arms). Primary endpoint: Relapse Free Survival. Planned start Mar 2018; status: withdrawn.
02
Drugs
arsenic trioxide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03377725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03377725.